SARS-CoV-2 must have multiple mechanisms because binding to just the ACE-2 is incapable of producing such severe disease. Targeting the galectin-like domain of the receptor binding domain (RBD) could be a cooperative therapy. The crystalline structure was evaluated and found that the Carbohydrate Recognition Domain (CRD) was located within the RBD and was a preserved site. The site is called the ganlioside-binding-domain (GBD) and also referred to as the galectin fold.